本书的作者简介中，获奖名目一段里以 个人获 三个字开头，把以单位名义获得的国家发明奖，泰国玛希顿医学贡献奖都包含在其中！ 书中的开篇文章题目是 青蒿素的发现 ，其后注明为 中国中医研究院中药研究所供稿 ，这样的写法实际上是把记录青蒿素真相的责任推给了单位，不知道这一单位供稿是否得到这个单位的党组集体决定后同意屠呦呦发表在此，记录于历史的纸上。 这里把本书的勘误表及作者补充说明登出，请读者使用。注意其中对参考文献内容的修改，但这个勘误表并不包括本书第 190 页上以个人名义替代中国抗疟药青蒿素及其衍生物研究协作组的参考文献 3 ，特别是这是英文文献，实际这样的文献引用出现在很多地方，是作者有意给外国学者提供虚假内容，国际上会如何看待中国的科学工作者呢？ 该文献正确的引用如下： China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials, Chemical Studies on Qinghaosu (Artemisinine), Journal of Traditional Chinese Medicine, 1982, 2(1):3-8. 该书中参考文献的p69的【5】, p140的【5】,p190的【3】都引用了这篇文献，居然名字还有屠呦呦和Tu Y Y两种。英文文献中怎么会有中文人名？其实这篇文章被这样引用可能会出现在很多评奖、学术刊物上，在各种有利于个人的事务上被利用，甚至可以说用来欺骗其他学者和科技管理者，必须正视！ 还值得思考的是，这个勘误表和补充说明为什么用作者，而不是编著者呢？难道这些错误是这个补充说明中参与编写的作者们补充说明的，而不是编著者屠呦呦的补充说明？
http://www.gopubmed.org/web/gopubmed/1?WEB03m36cxfaihruI10I1I00f01000j10040001rl 1980年《中国药理学报》的研究报告 1 of 2,022 documents semantically analyzed top author statistics Term: 1980 Description: year 1980 Top Years Publications 1980 1 Top Journals Publications Zhongguo Yao Li Xue Bao 1 Top Authors Publications Qu Z 1 Gu H 1 Lu B 1 Top Terms Publications Plasmodium berghei 1 Antimalarials 1 Artemisinins 1 Mice 1 Structure-Activity Relationship 1 Pyrans 1 Drug Resistance 1 Chloroquine 1 Animals 1 Sesquiterpenes 1 Title: PMID: 6461175 Related Articles Authors: Gu, H M , Lu, B F , Qu, Z X Journal: Zhongguo Yao Li Xue Bao , Vol. 1 (1): 48-50 , 1980 No abstract given. Pubmed MeSH: Animals , Chloroquine , Drug Resistance , Mice , Pyrans , Sesquiterpenes , Structure-Activity Relationship Wikipedia: Antimalarial drugs , Antimalarials , Artemisinins , Plasmodium berghe 1 2 Top Years Publications 2009 254 2008 228 2007 191 2006 176 2005 124 2004 111 2002 81 2001 78 2003 78 1998 77 1999 70 2000 67 1997 62 1994 54 2010 47 1996 40 1993 37 1995 34 1992 25 1989 24 1 2 1 2 3 4 5 Top Countries Publications USA 353 United Kingdom 158 China 157 Thailand 148 France 94 India 89 Switzerland 64 Sweden 62 Netherlands 60 Germany 56 Nigeria 34 Belgium 33 Australia 31 Italy 31 Vietnam 31 South Korea 29 Austria 24 Japan 21 South Africa 20 Kenya 18 1 2 3 4 5 1 2 3 ... 18 Top Cities Publications Bangkok 107 London 66 Liverpool 45 Washington 43 Geneva 39 Shanghai 35 Baltimore 32 Paris 31 Beijing 30 Amsterdam 28 Uppsala 28 Lucknow 26 Wien 23 Basel 22 Toulouse 19 Seattle 19 Stockholm 19 Ann Arbor 19 Mae Sot 18 Cape Town 17 1 2 3 ... 18 1 2 3 ... 25 Top Journals Publications Malar J 129 Am J Trop Med Hyg 100 T Roy Soc Trop Med H 84 J Med Chem 70 Antimicrob Agents Ch 56 Trop Med Int Health 47 Planta Med 38 Med Trop (mars) 35 Lancet 32 Yao Xue Xue Bao 30 Acta Trop 28 Ann Trop Med Parasit 27 Bioorg Med Chem Lett 26 Southeast Asian J Trop Med Public Health 23 J Nat Prod 20 Antimicrob Agents Chemother 18 Biochem Pharmacol 18 Zhongguo Yao Li Xue Bao 18 J Infect Dis 17 Plos One 17 1 2 3 ... 25 1 2 3 ... 244 Top Terms Publications Artemisinins 1,905 Antimalarials 1,623 Humans 1,190 Malaria 1,162 Sesquiterpenes 1,121 Pharmaceutical Preparations 1,062 Animals 1,052 Plasmodium falciparum 767 Malaria, Falciparum 593 Parasites 516 Chloroquine 404 Drug Resistance 391 Patients 371 Child 365 Adult 335 Drug Therapy, Combination 294 Evaluation Studies as Topic 291 Artemisia 258 Mefloquine 254 Mice 235 1 2 3 ... 244 1 2 3 ... 340 Top Authors Publications White N 74 Looareesuwan S 40 Nosten F 36 Olliaro P 28 Kager P 28 Ashton M 28 Peters W 27 Meshnick S 26 Posner G 24 Wernsdorfer W 23 Bjrkman A 22 Ward S 21 Avery M 20 Robinson B 19 Milhous W 18 Robert A 17 Haynes R 17 Davis T 17 De Vries P 17 Meunier B 16
看文章之前，非常希望这事和中国的产品质量无关。很可惜，美联社的新闻报道还是提及中国的产品有问题。质量就是生命，对于这个救命的药来说，一点都没有错。 青蒿素介绍： http://en.wikipedia.org/wiki/Artemisinin http://www.google.com/hostednews/ap/article/ALeqM5jVUMi8n37pNyXzx3YHl0TiJCekDAD9DO1I5G0 Bad malaria pills in Africa raise resistance fears By MARGIE MASON (AP) Feb 8, 2010 High rates of the most effective type of malaria-fighting drug s sold in three African countries are poor quality including nearly half the pills sampled in Senegal raising fears of increased drug resistance that could wipe out the last weapon left to battle a disease that kills 1 million people each year , according to a U.S. report released Monday. Between 16 percent and 40 percent of artemisinin-based drugs sold in Senegal, Madagascar and Uganda failed quality testing, including having impurities or not containing enough active ingredient , the survey found. Artemisinin-based drugs are the only affordable treatment for malaria left in the global medicine cabinet. Other drugs have already lost effectiveness due to resistance , which builds when not enough medicine is taken to kill all of the mosquito-transmitted parasites. If artemisinin-based drugs stop working, there is no good replacement and experts worry many people could die. It is worrisome that almost all of the poor-quality data that was obtained was a result of inadequate amounts of active (ingredients) or the presence of impurities in the product, said Patrick Lukulay, director of a nongovernmental U.S. Pharmacopeia program funded by the U.S. government, which conducted the survey. This is a disturbing trend that came to light. The study is the first part of a 10-country examination of antimalarials in Africa by the U.S. and the World Health Organization. It follows evidence from the Thai-Cambodian border that artemisinin-based drugs there are taking longer to cure malaria patients, the first sign of drug resistance. The three-country report also found bad drugs in both the public and private health sectors, meaning governments some buying medicines with donor funds are not doing enough to keep poor-quality pills out. All of the drugs tested from the public sector in Uganda, however, passed the quality tests. But 40 percent of the artemisinin-based drugs in Senegal failed. There are countries where donated medicines are not subjected to quality controls, they're just accepted, said Lukulay. There are countries in Africa where Chinese products have been donated and found to be unacceptable later in the public sector. A total of 444 samples of artemisinin-based combination drugs along with the antimalarial sulfadoxine-pyrimethamine to which resistance has already developed were first screened locally using visual inspection and basic lab tests. Sulfadoxine-pyrimethamine is still used, mainly for preventative treatment for pregnant women. Nearly 200 samples then underwent full quality control testing in a U.S. laboratory to examine the amount of active ingredient present and drug purity. For both drugs, 44 percent from Senegal failed the full quality testing, followed by 30 percent from Madagascar and 26 percent from Uganda. While the study is not the first to assess the quality of antimalarials in Africa, it is the most rigorous and complete. Similar failure rates were found in previous work, but those did not focus specifically on artemisinin-based drugs. I am alarmed by these results because it means there are many cases of malaria that are being only partially treated, and that just guarantees acceleration of artemisinin drug resistance, said Rachel Nugent, deputy director for Global Health at the Center for Global Development, a U.S. think tank. It is the most comprehensive study out there on antimalarials and should be a wake-up call. Nugent was not involved in the study. In all three countries, the antimalarial brands collected from various areas and sectors tended to either do well across the board or poorly, which could prove helpful for governments working to ban low-grade drugs. Results from the other countries surveyed Cameroon, Ethiopia, Ghana, Kenya, Malawi, Nigeria and Tanzania have not yet been publicly released by the WHO. But Clive Ondari, who worked on the study for the WHO in Geneva, said failure rates in three of those countries were also significantly high. Ghana has already withdrawn more than 20 drugs from the market after receiving the initial results, Lukulay said. Associated Press Writer Justin Pritchard in Los Angeles contributed to this report. On the Net: http://www.usp.org/ Copyright 2010 The Associated Press. All rights reserved.
标签: 青蒿素
